KOSS Relative Valuation
KOSS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KOSS is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.48
P/B
Median3y
1.68
Median5y
2.99
-0.82
FCF Yield
Median3y
7.32
Median5y
5.21
Competitors Valuation Multiple
The average P/S ratio for KOSS's competitors is 0.14, providing a benchmark for relative valuation. Koss Corp Corp (KOSS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 5.86%, this premium appears unsustainable.
People Also Watch
PRTC
PureTech Health PLC
17.550
USD
-0.62%
TBPH
Theravance Biopharma Inc
10.370
USD
-0.19%
ACTG
Acacia Research Corp
3.160
USD
+0.32%
METC
Ramaco Resources Inc
10.000
USD
+0.50%
YRD
Yiren Digital Ltd
6.380
USD
-2.60%
DCGO
DocGo Inc
2.310
USD
+5.00%
GRVY
Gravity Co Ltd
60.150
USD
+0.86%
FLX
BingEx Ltd
2.290
USD
+2.69%
TCMD
Tactile Systems Technology Inc
14.080
USD
+1.81%
AHG
Akso Health Group
1.361
USD
-2.79%
FAQ
Is Koss Corp (KOSS) currently overvalued or undervalued?
Koss Corp (KOSS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Koss Corp (KOSS) is between to according to relative valuation methord.
What is Koss Corp (KOSS) fair value?
How does KOSS's valuation metrics compare to the industry average?
What is the current P/B ratio for Koss Corp (KOSS) as of May 04 2025?
What is the current FCF Yield for Koss Corp (KOSS) as of May 04 2025?
What is the current Forward P/E ratio for Koss Corp (KOSS) as of May 04 2025?